ArticleIntensive care medicine experimental2026
Sepsis-induced endothelial glycocalyx disruption and remodeling: an ultrastructural study in mice.
Article in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSepsis damages endothelial cells through glycocalyx degradation, contributing to organ dysfunction. Glycocalyx repair is essential for recovery, but the underlying mechanisms remain unclear. Rhamnan sulfate (RS), a sulfated polysaccharide with anti-inflammatory properties, may support endothelial glycocalyx repair. In this study, we investigated the glycocalyx repair process and the therapeutic potential of RS using a mouse sepsis model.
methodsSepsis was induced in male C57BL/6 mice by cecal ligation and puncture (CLP). Mice were divided into the RS, control (CTL), and sham groups. RS was orally administered to the RS group, while the CTL group received no treatment after CLP. Sham mice underwent laparotomy only without CLP. Endothelial glycocalyx repair was evaluated using transmission electron microscopy (TEM) and scanning electron microscopy (SEM), and quantitative TEM analysis. Gene expressions of glycocalyx-related enzymes and inflammatory cytokines were assessed in liver and small intestine tissues by quantitative real-time PCR.
resultsThe 7-day survival rate after CLP was significantly higher in the RS group (55%) than in the CTL group (25%). TEM and SEM demonstrated that in the CTL group, the endothelial glycocalyx remained disrupted for up to 72 h after CLP but by two weeks had undergone compensatory regeneration with thickening, exceeding that observed in sham-treated mice. In contrast, in the RS group, glycocalyx continuity was restored by 72 h and normalized to levels comparable to those of the sham-treated group by two weeks. Quantitative TEM analysis supported marked structural alteration of glycocalyx after CLP and normalization of glycocalyx thickness toward sham levels after RS treatment. Quantitative real-time PCR revealed a significant increase in inflammatory cytokines (IL-1β, IL-6, TNF-α) after CLP, which tended to be lower in the RS-treated group. A similar trend was observed for the glycocalyx-degrading enzymes heparanase and hyaluronidase, whose expression was also suppressed by RS treatment.
conclusionsElectron microscopy allowed detailed observation of endothelial glycocalyx repair in septic mice. RS promoted glycocalyx repair and reduced inflammation, suggesting that administration of RS may be a novel therapeutic strategy for maintaining vascular integrity in sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.